BIBW 2992 in non-small cell lung cancer

Bibliography

• Sibilia M, Kroismayr R, Lichtenberger BM, the epidermal growth factor receptor: from development to tumorigenesis. Differentiation 2008;75(9):770-87
   Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Langer CJ, Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies. Lung Cancer 2003;41(Suppl 1):S32-7
   PubMedGoogle Scholar
• Kancha RK, von Bubnoff N, Peschel C, Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res 2009;15:460-7
   PubMed Web of Science ®Google Scholar
• Gazdar AF. Activating and resistance mutations of EGFR in non-small cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S24-31
   PubMed Web of Science ®Google Scholar
• Riely GJ, Pao W, Pham D, Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006;12(3 Pt 1):839-44
   PubMed Web of Science ®Google Scholar
• Leidner RS, Fu P, Clifford B, Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. J Clin Oncol 2009;27(33):5620-6
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC, Erlotinib in lung cancer – molecular and clinical predictors of outcome. N Engl J Med 2005;353(2):133-44
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353(2):123-32
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350(21):2129-39
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57
   PubMed Web of Science ®Google Scholar
• Massarelli E, Varella-Garcia M, Tang X, KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13(10):2890-6
   PubMed Web of Science ®Google Scholar
• Kono SA, Marshall ME, Ware KE, Heasley LE. The fibroblast growth factor receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug Resist Update 2009;12(4-5):95-102
   PubMed Web of Science ®Google Scholar
• Kosaka T, Yatabe Y, Endoh H, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib, Clin Cancer Res 2006;12(19):5764-9
   PubMed Web of Science ®Google Scholar
• Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008;26(10):1742-51
   PubMed Web of Science ®Google Scholar
• Clark J, Cools J, Gilliland DG. EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head. PLoS Med 2005;2:e75
   PubMed Web of Science ®Google Scholar
• Yun CH, Mengwasser KE, Toms AV, the T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008;105:2070-5
   PubMed Web of Science ®Google Scholar
• van der Veeken J, Oliveira S, Schiffelers RM. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009;9(6):748-60
   PubMed Web of Science ®Google Scholar
• Suda K, Murakami I, Katayama T, Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010;16(22):5489-98
   PubMed Web of Science ®Google Scholar
• Li D, Ambrogio L, Shimamura T, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008;27(34):4702-11
   PubMed Web of Science ®Google Scholar
• Regales L, Gong Y, Shen R. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest 2009;119(10):3000-10
   PubMed Web of Science ®Google Scholar
• Eskens FALM, Mom CH, Planting AST, A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008;98:80-5
   PubMed Web of Science ®Google Scholar
• Stopfer P, Narjes H, Gaschler-Markefski B, Pharmacokinetics (PK) of [14C]-BIBW 2992 after administration of a single dose of 15 mg [14C]-BIBW 2992 oral solution in healthy male volunteers. J Clin Oncol 2008;26(18 Suppl): abstract 14607
   Google Scholar
• Lewis N, Marshall J, Amelsberg A, A phase I dose escalation schedule of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors [abstract 3091]. J Clin Oncol 2006;24(18 Suppl):143s
   Web of Science ®Google Scholar
• Yap TA, Vidal L, Adam J, Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010;28(925):3965-72
   PubMedGoogle Scholar
• Agus DB, Terlizzi E, Stopfer P, A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/ER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours [abstract 2074]. J Clin Oncol 2006;24(18 Suppl):97s
   Web of Science ®Google Scholar
• Vermorken JB, Machiels JH, Rottey S, Phase Ib study evaluating the combination of BIBW 2992 with two different standard chemotherapy regimens, cisplatin/paclitaxel (PT) and cipslatin/5FU (PF), in patients with advanced solid tumors. J Clin Oncol 2010;28(18 Suppl): abstract e13521
   PubMedGoogle Scholar
• Ang J, Mikropoulos C, Stavridi F, A phase I study of daily BIBW 2992, an irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel. J Clin Oncol 2009;27(18 Suppl): abstract e14541
   Google Scholar
• Awada AH, Dumez H, Wolter P, A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three weekly docetaxel in patients with advanced solid tumors. J Clin Oncol 2009;27(18 Suppl): abstract 3556
   Google Scholar
• Yang C, Hirsch J, Cadranel Y, Phase IIb/III double-blind randomized trial of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus best supportive care (BSC) versus placebo plus BSC in patients with NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or gefitinib (LUX-Lung1): A preliminary report. J Clin Oncol 2009;27(Suppl 15s): abstract 8062
   Google Scholar
• Miller VA, Hirsh V, Cadranel J, Phase IIB/III double-blind randomized trial of afatinib (BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo 1 + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-LUNG 1). Ann Oncol 2010;21(Suppl 8):viii1. Abstract LBA1
   Google Scholar
• Yang C, Shih J, Su W, A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). J Clin Oncol 2010;28(Suppl 15s): abstract 7521
   Google Scholar
• Bean J, Riely GJ, Balak M, Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008;14(22):7519-25
   PubMed Web of Science ®Google Scholar
• Takezawa K, Okamoto I, Tanizaki J, Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 2010;9(6):1647-56
   PubMed Web of Science ®Google Scholar